Bone cancer: Clinical Practice Guidelines in Oncology™

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 5, Issue 4, 2007, Pages 420-437

  Biermann, J Sybil ^a   Adkins, Douglas ^a   Benjamin, Robert ^a   Brigman, Brian ^a   Chow, Warren ^a   Conrad III, Ernest U ^a   Frassica, Deborah ^a   Frassica, Frank J ^a   George, Suzanne ^a   Healey, John H ^a   Heck Jr , Robert ^a   Letson, G Douglas ^a   Mayerson, Joel ^a   McGarry, Sean V ^a   O'Donnell, Richard J ^a   Patt, Joshua ^a   Randall, R Lor ^a   Santana, Victor ^a   Satcher, Robert L ^a   Schmidt, Richard G ^a   Siegel, Herrick J ^a   Wong, Michael K ^a   Yasko, Alan W ^a   more..

^a NONE

Author keywords

Bone cancer; Chondrosarcomas; Ewing's sarcoma; Fibrosarcomas; Metastasis; NCCN Clinical Practice Guidelines; Osteosarcomas; Radiation therapy; Sarcoma; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GROWTH FACTOR; IFOSFAMIDE; VINCRISTINE;

BONE BIOPSY; BONE CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CHONDROSARCOMA; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; EWING SARCOMA; FOLLOW UP; HISTOPATHOLOGY; HUMAN; ORTHOPEDIC SURGERY; PRACTICE GUIDELINE; UNITED STATES; BONE TUMOR; PATHOLOGY; REVIEW;

BONE NEOPLASMS; HUMANS;

EID: 34248216469     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2007.0037     Document Type: Conference Paper

References (118)

1. Yasko AW, Warren C. Bone sarcomas. In: Pazdur R, Hoskins WJ, Coia LR, Wagman LD, eds. Cancer Management: A Multidisciplinary Approach. 9th ed. Manhasset, NY: CMP; 2005:573-584.
2. Dorfman HD, Czerniak B. Bone cancers. Cancer 1995;75(suppl 1):203-210.
3. Unni KK. Dahlin's Bone Tumors: General Aspects and Data on 11,087 Cases. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 1996:144-250.
4. Gurney JG, Severson RK, Davis S, Robison LL. Incidence of cancer in children in the United States. Sex-, race-, and 1-year age-specific rates by histologic type. Cancer 1995;75:2186-2195.
5. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
6. Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004;9:422-441.
7. Wittig JC, Bickels J, Priebat D, et al. Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. Am Fam Physician 2002;65:1123-1132.
8. Gier HE. The Ewing's family of tumors. Ewing's sarcoma and primitive neuroectodermal tumors. Pediatr Clin North Am 1997;44: 991-1004.
9. Sagerman RH, Cassady JR, Tretter P, Ellsworth RM. Radiation induced neoplasia following external beam therapy for children with retinoblastoma. Am J Roentgenol Radium Ther Nucl Med 1969;105:529-535.
10. Tucker MA, D'Angio GJ, Boice JD Jr, et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 1987;317:588-593.
11. Araki N, Uchida A, Kimura T, et al. Involvement of the retinoblastoma gene in primary osteosarcomas and other bone and soft-tissue tumors. Clin Orthop Relat Res1991;270:271-277.
12. Schimke RN, Lowman JT, Cowan AB. Retinoblastoma and osteogenic sarcoma in siblings. Cancer 1974;34:2077-2079.
13. McIntyre JF, Smith-Sorenson B, Friend SH, et al. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol 1994;12:925-930.
14. Li FP, Fraumeni JF Jr. Prospective study of a family cancer syndrome. JAMA 1982;247:2692-2694.
15. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-1238.
16. Miller CW, Aslo A, Won A, et al. Alterations of the p53, Rb and MDM2 genes in osteosarcoma. J Cancer Res Clin Oncol 1996;122:559-565.
17. Avigad S, Cohen IJ, Zilberstein J, et al. The predictive potential of molecular detection in the nonmetastatic Ewing family of tumors. Cancer 2004;100:1053-1058.
18. de Alva E, Kawai A, Healy JH, et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol 1998;16:1248-1255.
19. Denny CT. Gene rearrangements in Ewing's sarcoma. Cancer Invest 1996;14:83-88.
20. Glaubiger DL, Makuch R, Schwarz J, et al. Determination of prognostic factors and their influence on therapeutic results in patients with Ewing's sarcoma. Cancer 1980;45:2213-2219.
21. Zoubeck A, Dockhorn-Dworniczak B, Delattre O, et al. Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol 1996;14:1245-1251.
22. Kruzelock RP, Murphy EC, Strong LC, et al. Localization of a novel tumor suppressor locus on human chromosome 3q important in osteosarcoma tumorigenesis. Cancer Res 1997;57:106-109.
23. Yamaguchi T, Toguchida J, Yamamuro T, et al. Allelotype analysis in osteosarcomas: frequent allele loss on 3q, 13q, 17p, and 18q. Cancer Res 1992;52:2419-2423.
24. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 1980;153:106-120.
25. Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24:2917-2931.
26. Rougraff BT, Kneisl JS, Simon MA. Skeletal metastases of unknown origin. A prospective study of a diagnostic strategy. J Bone Joint Surg Am 1993;75:1276-1281.
27. Heck RK Jr, Peabody TD, Simon MA. Staging of primary malignancies of bone. CA Cancer J Clin 2006;56:366-375.
28. Schuetze SM. Utility of positron emission tomography in sarcomas. Curr Opin Oncol 2006;18:369-373.
29. 18F] Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol 2005;23:8828-8834.
30. Hawkins DS, Rajendran JG, Conrad EU III, et al. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography. Cancer 2002;94:3277-3284.
31. Terek RM. Recent advances in the basic science of chondrosarcoma. Orthop Clin North Am 2006;37:9-14.
32. Bovee JV, Cleton-Jansen AM, Taminiau AH, Hogendoorn PC. Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncol 2005; 6:599-607.
33. Mankin HJ, Cantley KD, Lippiello L, et al. The biology of human chondrosarcoma. I. Description of the cases, grading, and biochemical analyses. J Bone Joint Surg Am 1980;62: 160-176.
34. Mankin HJ, Cantley KD, Schiller AL, Lippeillo L. The biology of human chondrosarcoma. II. Variation in chemical composite among types and subtypes of benign and malignant cartilage tumors. J Bone Joint Surg Am 1980;62:176-188.
35. Bruns J, Elbracht M, Niggemeyer O. Chondrosarcoma of bone: an oncological and functional follow-up study. Ann Oncol 2001; 12:859-864.
36. Fiorenza F, Abudu A, Grimer RJ, et al. Risk factors for survival and local control in chondrosarcoma of bone. J Bone Joint Surg Br 2002;84:93-99.
37. Huvos AG. Bone Tumors: Diagnosis, Treatment and Prognosis. Philadelphia: WB Saunders Co.; 1979.
38. Lee FY, Mankin HJ, Fondren G, et al. Chondrosarcoma of bone: an assessment of outcome. J Bone Joint Surg Am 1999;81: 326-338.
39. Sanerkin NG. The diagnosis and grading of chondrosarcoma of bone: a combined cytologic and histologic approach. Cancer 1980;45:582-594.
40. Sives TS, Wold LE, Dahlin DC, et al. Chondrosarcoma and its variants. In: Sim FH, ed. Diagnosis and Treatment of Bone Tumors: A Team Approach. Thorofare, NJ: Slack; 1988:211-217.
41. Ahmed AR, Tan TS, Unni KK, et al. Secondary chondrosarcoma in osteochondroma: report of 107 Patients. Clin Orthop Relat Res 2003;411:193-206.
42. Bergh P, Gunterberg B, Meis-Kindblom JM, Kindblom LG. Prognostic factors and outcome of pelvic, sacral, and spinal chondrosarcomas: a center-based study of 69 cases. Cancer 2001; 91:1201-1212.
43. Enneking WF, Dunham WK. Resection and reconstruction for primary neoplasms involving the innominate bone. J Bone Joint Surg Am 1978;60:731-746.
44. Norman A, Sissons HA. Radiographic hallmarks of peripheral chondrosarcoma. Radiology 1984;151:589-596.
45. Mankin HJ, Fogelson FS, Thrasher AZ, Jaffer F. Massive resection and allograft transplantation in the treatment of malignant bone tumors. N Engl J Med 1976;294:1247-1255.
46. Marcove RC, Mike V, Hutter RV, et al. Chondrosarcoma of the pelvis and upper end of femur. An analysis of factors influencing survival time in one hundred and thirteen cases. J Bone Joint Surg Am 1972;54:561-572.
47. Marcove RC, Stovell PB, Huvos AG, Bullough PG. The use of cryosurgery in the treatment of low and medium grade chondrosarcoma. A preliminary report. Clin Orthop Relat Res 1977;122:147-156.
48. Marcove RC. A 17-year review of cryosurgery in the treatment of bone tumors. Clin Orthop Relat Res 1982;163:231-234.
49. Marcove RC. Chondrosarcoma: diagnosis and treatment. Orthop Clin North Am 1977;8:811-820.
50. Pring ME, Weber KL, Unni KK, Sim FH. Chondrosarcoma of the pelvis. A review of sixty-four cases. J Bone Joint Surg Am 2001;83:1630-1642.
51. Pritchard DJ, Lunke RJ, Taylor WF, et al. Chondrosarcoma: a clinicopathologic and statistical analysis. Cancer 1980;45: 149-157.
52. Sim FH, Bowman WE, Chao EY. Limb salvage surgery and reconstructive techniques. In: Sim FH, ed. Diagnosis and Treatment of Bone Tumors: A Team Approach. Thorofare, NJ: Slack; 1988: 75-105.
53. Noel G, Feuvret L, Ferrand R, et al. Radiotherapeutic factors in the management of cervical-basal chordomas and chondrosarcomas. Neurosurgery 2004;55:1252-1260; discussion 1260-1262.
54. Hug EB, Slater JD. Proton radiation therapy for chordomas and chondrosarcomas of the skull base. Neurosurg Clin N Am 2000;11:627-638.
55. de Alava E, Gerald WL. Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor family. J Clin Oncol 2000;18:204-213.
56. Bernstein M, Kovar H, Paulussen M, et al. Ewing's sarcoma family of tumors: current management. Oncologist 2006;11: 503-519.
57. Ambros IM, Ambros PF, Strehl S, et al. MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. Cancer 1991;67: 1886-1893.
58. Dehner LP. Primitive neuroectodermal tumor and Ewing's sarcoma. Am J Surg Pathol 1993;17:1-13.
59. Delattre O, Zucman J, Melot T, et al. The Ewing family of tumors - a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 1994;331:294-299.
60. Horowitz ME, Malawer MM, Woo SY, et al. Ewing's sarcoma family of tumors: Ewing's sarcoma of bone. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 1997: 831-838.
61. Kissane JM, Askin FB, Foulkes M, et al. Ewing's sarcoma of bone: clinicopathologic aspects of 303 cases from the Intergroup Ewing's Sarcoma Study. Hum Pathol 1983;14:773-779.
62. Perlman EJ, Dickman PS, Askin FB, et al. Ewing's sarcoma - routine diagnostic utilization of MIC2 analysis: a Pediatric Oncology Group/Children's Cancer Group Intergroup Study. Hum Pathol 1994;25:304-307.
63. Tsokos M. Peripheral primitive neuroectodermal tumors. Diagnosis, classification, and prognosis. In: Garvin AJ, O'Leary TJ, Bernstein J, Rosenberg HS, eds. Pediatric Molecular Pathology: Quantitation and Applications. Basel: Karger, 1992:27-98.
64. Cangir A, Vietti TJ, Gehan EA, et al. Ewing's sarcoma metastatic at diagnosis. Results and comparisons of two Intergroup Ewing's Sarcoma Studies. Cancer 1990;66:887-893.
65. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000;18:3108-3114.
66. Göbel V, Jurgens H, Etspuler G, et al. Prognostic significance of tumor volume in localized Ewing's sarcoma of bone in children and adolescents. J Cancer Res Clin Oncol 1987;113:187-191.
67. Mendenhall CM, Marcus RB Jr, Enneking WF, et al. The prognostic significance of soft tissue extension in Ewing's sarcoma. Cancer 1983;51:913-917.
68. Brown AP, Fixsen JA, Plowman PN. Local control of Ewing's sarcoma: an analysis of 67 patients. Br J Radiol 1987;60:261-268.
69. Scully SP, Temple HT, O'Keefe RJ, et al. Role of surgical resection in pelvic Ewing's sarcoma. J Clin Oncol 1995;13:2336-2341.
70. Rosen G, Caparros B, Nirenberg A, et al. Ewing's sarcoma: ten-year experience with adjuvant chemotherapy. Cancer 1981;47: 2204-2213.
71. Nesbit ME Jr, Gehan EA, Burgert EO Jr, et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol 1990;8:1664-1674.
72. Burgert EO Jr, Nesbit ME, Garnsey LA, et al. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: Intergroup study IESS-II. J Clin Oncol 1990;8:1514-1524.
73. Smith MA, Ungerleider RS, Horowitz ME, Simon R. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst 1991;83:1460-1470.
74. Bacci G, Picci P, Ferrari S, et al. Neoadjuvant chemotherapy for Ewing's sarcoma of bone: no benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase - results of two sequential studies. Cancer 1998;82:1174-1183.
75. Paulussen M, Ahrens S, Dunst J, et al. Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol 2001;19:1818-1829.
76. Kolb EA, Kushner BH, Gorlick R, et al. Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. J Clin Oncol 2003;21: 3423-3430.
77. Bacci G, Ferrari S, Longhi A, et al. Therapy and survival after recurrence of Ewing's tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Ann Oncol 2003;14:1654-1659.
78. Bacci G, Forni C, Longhi A, et al. Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992. Eur J Cancer 2004;40:73-83.
79. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of Ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003;348: 694-701.
80. Miser JS, Krailo MD, Tarbell NJ, et al. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide - a Children's Cancer Group and Pediatric Oncology Group study. J Clin Oncol 2004;22:2873-2876.
81. Horowitz ME, Kinsella TJ, Wexler LH, et al. Total body irradiation and autologous bone marrow transplantation in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma. J Clin Oncol 1993;11:1911-1918.
82. Burdach S, Jurgens H, Peters C, et al. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. J Clin Oncol 1993;11:1482-1488.
83. Kushner BH, Meyers PA. How effective is dose-intensive/ myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review. J Clin Oncol 2001;19:870-880.
84. Hendershot E. Treatment approaches for metastatic Ewing's sarcoma: a review of the literature. J Pediatr Oncol Nurs 2005;22: 339-352.
85. Barker LM, Pendergrass TW, Sanders JE, Hawkins DS. Survival after recurrence of Ewing's sarcoma family of tumors. J Clin Oncol 2005;23:4354-4362.
86. McTiernan A, Driver D, Michelagnoli MP, et al. High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing's sarcoma family of tumours. Ann Oncol 2006;17:1301-1305.
87. Oberlin O, Rey A, Desfachelles AS, et al. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Societe Francaise des Cancers de l'Enfant. J Clin Oncol 2006;24:3997-4002.
88. Pritchard DJ, Dahlin DC, Dauphine RT, et al. Ewing's sarcoma. A clinicopathological and statistical analysis of patients surviving five years or longer. J Bone Joint Surg Am 1975;57:10-16.
89. Gorlick RG, Meyers PA, Marina N. Osteosarcoma: a review of current management and future clinical trial directions. In: American Society of Clinical Oncology 2006 Educational Book. Alexandria, VA:ASCO; 2006:558-561.
90. Longhi A, Errani C, De Paolis M, et al. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 2006;32: 423-436.
91. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 1994;12:423-431.
92. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002;20: 776-790.
93. Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986;314:1600-1606.
94. Eilber F, Giuliano A, Eckhardt J, et al. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 1987;5:21-26.
95. Link MP, Goorin AM, Horowitz M, et al. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma study. Clin Orthop Relat Res 1991;270:8-14.
96. Bacci G, Picci P, Ruggieri P, et al. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Instituto Rizzoli experience in 127 patients treated post-operatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer 1990;65:2539-2553.
97. Meyers PA, Heller G, Healy J, et al. Chemotherapy for non-metastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992;10:5-15.
98. Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/Osteosarcoma-2 protocol: an updated report. J Clin Oncol 2000;18:4016-4027.
99. Bramwell VH, Burgers M, Sneath R, et al. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol 1992;10: 1579-1591.
100. Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of non-metastatic osteosarcoma of the extremity with preoperative and post-operative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 1997;15:76-84.
101. Bacci G, Ferrari S, Longhi A, et al. Neoadjuvant chemotherapy for high-grade osteosarcoma of the extremities: long-term results for patients treated according to the Rizzoli IOR/OS-3b protocol. J Chemother 2001;13:93-99.
102. Meyer WH, Pratt CB, Poquette CA, et al. Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial. J Clin Oncol 2001;19: 171-182.
103. Goorin AM, Schwartzentruber DJ, Devidas M, et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 2003;21: 1574-1580.
104. Zalupski MM, Rankin C, Ryan JR, et al. Adjuvant therapy of osteosarcoma - a phase II trial: Southwest Oncology Group study 9139. Cancer 2004;100:818-825.
105. Ferrari S, Smeland S, Mercuri M, et al. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 2005;23:8845-8852.
106. Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005;23:2004-2011.
107. Hauben EI, Weeden S, Pringle J, et al. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. Eur J Cancer 2002;38:1218-1225.
108. Bacci G, Ruggieri P, Picci P, et al. Intra-arterial versuss intravenous cisplatinum (in addition to systemic Adriamycin and high-dose methotrexate) in the neoadjuvant treatment of osteosarcoma of the extremities. Results of a randomized study. J Chemother 1996;8:70-81.
109. Bacci G, Ferrari S, Tienghi A, et al. A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity. Eur J Surg Oncol 2001;27:98-104.
110. Winkler K, Bielack S, Delling G, et al. Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86). Cancer 1990;66:1703-1710.
111. Bacci G, Briccoli A, Mercuri M, et al. Osteosarcoma of the extremities with synchronous lung metastases: long-term results in 44 patients treated with neoadjuvant chemotherapy. J Chemother 1998;10:69-76.
112. Marina NM, Pratt CB, Rao BN, et al. Improved prognosis of children with osteosarcoma metastatic to the lung(s) at the time of diagnosis. Cancer 1992;70:2722-2727.
113. Meyers PA, Heller G, Healey JH, et al. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol 1993;11:449-453.
114. Bacci G, Briccoli A, Rocca M, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol 2003;14: 1126-1134.
115. Hartmann O. New strategies for the application of high-dose chemotherapy with hematopoietic support in pediatric solid tumours. Ann Oncol 1995;6(suppl 4):13-16.
116. Goorin AM, Harris MB, Bernstein M, et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol 2002;20:426-433.
117. Tabone MD, Kalifa C, Rodary C, et al. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy. J Clin Oncol 1994;12:2614-2620.
118. Saeter G, Hoie J, Stenwig AE, et al. Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival. Cancer 1995;75:1084-1093.